Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2015

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for
the fourth quarter and fiscal year 2015.

Fourth quarter 2015 results:

  • Revenue of $592 million, a 15% increase compared to $512 million in
    the fourth quarter of 2014, and an increase of 19% on a constant
    currency basis
  • GAAP net income attributable to Illumina stockholders for the quarter
    of $104 million, or $0.70 per diluted share, compared to $153 million,
    or $1.03 per diluted share, for the fourth quarter of 2014
  • Non-GAAP net income attributable to Illumina stockholders for the
    quarter of $121 million, or $0.81 per diluted share, compared to $129
    million, or $0.87 per diluted share, for the fourth quarter of 2014
    (see the table entitled “Itemized Reconciliation Between GAAP and
    Non-GAAP Net Income Attributable to Illumina Stockholders” for a
    reconciliation of these GAAP and non-GAAP financial measures)
  • Cash flow from operations of $240 million and free cash flow of $205
    million for the quarter

Gross margin in the fourth quarter of 2015 was 69.4% compared to 75.1%
in the prior year period. Excluding the effect of non-cash stock
compensation expense, amortization of acquired intangible assets, legal
contingencies, and impairments, non-GAAP gross margin was 71.7% for the
fourth quarter of 2015 compared to 72.3% in the prior year period.

Research and development (R&D) expenses for the fourth quarter of 2015
were $114.3 million compared to $142.9 million in the prior year period.
R&D expenses included $10.8 million and $11.8 million of non-cash stock
compensation expense in the fourth quarters of 2015 and 2014,
respectively. Excluding these charges, contingent compensation, legal
contingencies, and impairments, R&D expenses as a percentage of revenue
were 17.5% compared to 15.7% in the prior year period.

Selling, general and administrative (SG&A) expenses for the fourth
quarter of 2015 were $147.3 million compared to $122.2 million in the
prior year period. SG&A expenses included $21.4 million and $23.7
million of non-cash stock compensation expense in the fourth quarters of
2015 and 2014, respectively. Excluding these charges, amortization of
acquired intangible assets, and contingent compensation, SG&A expenses
as a percentage of revenue were 20.9% compared to 18.9% in the prior
year period.

Depreciation and amortization expenses were $32.8 million and capital
expenditures were $35.5 million during the fourth quarter of 2015. The
company settled $28.6 million of the 0.25% Convertible Senior Notes due
2016 and repurchased $202.0 million of common stock under the previously
announced discretionary and 10b5-1 share repurchase programs. At the
close of the quarter, the company held $1.39 billion in cash, cash
equivalents and short-term investments, compared to $1.34 billion as of
December 28, 2014.

Fiscal 2015 results:

  • Revenue of $2,220 million, a 19% increase compared to $1,861 million
    in fiscal 2014, and an increase of 23% on a constant currency basis
  • GAAP net income attributable to Illumina stockholders of $462 million,
    or $3.10 per diluted share, compared to $353 million, or $2.37 per
    diluted share, in fiscal 2014
  • Non-GAAP net income attributable to Illumina stockholders of $495
    million, or $3.32 per diluted share, compared to $407 million, or
    $2.74 per diluted share, in fiscal 2014 (see the table entitled
    “Itemized Reconciliation Between GAAP and Non-GAAP Net Income
    Attributable to Illumina Stockholders” for a reconciliation of these
    GAAP and non-GAAP financial measures)
  • Cash flow from operations of $660 million and free cash flow of $517
    million for the fiscal year

Gross margin for fiscal 2015 was 69.8% compared to 69.7% in the prior
year. Excluding the effect of non-cash stock compensation expense,
amortization of acquired intangible assets, legal contingencies, and
impairments, non-GAAP gross margin was 72.4% for fiscal 2015 compared to
71.7% in the prior year.

Research and development (R&D) expenses for fiscal 2015 were $401.5
million compared to $388.1 million in the prior year. R&D expenses
included $42.0 million and $50.9 million of non-cash stock compensation
expense in fiscal 2015 and 2014, respectively. Excluding these charges,
contingent compensation, legal contingencies, and impairments, R&D
expenses as a percentage of revenue were 16.2% compared to 15.3% in the
prior year.

Selling, general and administrative (SG&A) expenses for fiscal 2015 were
$524.7 million compared to $466.3 million in the prior year. SG&A
expenses included $79.1 million and $91.0 million of non-cash stock
compensation expense in fiscal 2015 and 2014, respectively. Excluding
these charges, amortization of acquired intangible assets, and
contingent compensation, SG&A expenses as a percentage of revenue were
19.8% compared to 19.5% in the prior year.

“We closed 2015 with strong momentum as fourth quarter orders and
revenue exceeded our expectations,” stated Jay Flatley, CEO. “Our recent
product announcements of MiniSeq™ and Infinium® XT further enhance the
most extensive genomics portfolio available. This portfolio, combined
with our investments in Project Firefly, Helix, and GRAIL, will position
us for long-term growth as we enable our continued penetration of the
enormous markets ahead.”

Updates since our last earnings release:

  • Announced the formation of GRAIL, a new company to enable asymptomatic
    cancer screening through the development of a pan-cancer screening test
  • Launched the MiniSeq System, a flexible benchtop sequencer priced
    at $49,500, and cost-efficient to run, which will allow virtually any
    laboratory to adopt next-generation sequencing (NGS), regardless of
    sample volume
  • Launched Infinium XT, a 96-sample BeadChip offering laboratories the
    ability to perform genotyping on larger numbers of samples
  • Previewed Project Firefly, a highly-reliable, easy-to-use NGS platform
    available in the second half of 2017 that will minimize hands-on time
    for both library preparation and sequencing
  • Launched EpiSeq™, an NGS service for epidemiological monitoring and
    control of healthcare-associated infections, in partnership with
    bioMérieux
  • Entered into partnership with Bio-Rad Laboratories, Inc. to develop an
    NGS workflow for single-cell analysis
  • Entered into a collaboration with Novogene to develop clinical
    applications in the fields of reproductive health and oncology based
    on Illumina’s NGS technology

Financial outlook and guidance

The non-GAAP financial guidance discussed below reflects certain pro
forma adjustments to assist in analyzing and assessing our core
operational performance. Please see our Reconciliation of Non-GAAP
Financial Guidance included in this release for a reconciliation of the
GAAP and non-GAAP financial measures.

For fiscal 2016, the Company is projecting approximately 16% revenue
growth, assuming current exchange rates, and non-GAAP earnings per
diluted share attributable to Illumina stockholders of $3.55 to $3.65.
These projections assume full year non-GAAP gross margin of
approximately 73% and a net loss attributable to non-controlling
interests of approximately $30 million. Full-year weighted average
diluted shares outstanding, for the measurement of pro forma amounts, is
expected to be approximately 149 million shares.

Quarterly conference call information

The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern
Time) on Tuesday, February 2, 2016. Interested parties may listen to the
call by dialing 888.687.3295 (passcode: 21551023), or if outside North
America by dialing +1.503.406.4070 (passcode: 21551023). Individuals may
access the live teleconference in the Investor Relations section of
Illumina’s web site under the “company” tab at www.illumina.com.

A replay of the conference call will be available from 5:00 pm Pacific
Time (8:00 pm Eastern Time) on February 2, 2016 through February 9, 2016
by dialing 855.859.2056 (passcode: 21551023), or if outside North
America by dialing +1.800.585.8367 (passcode: 21551023).

Statement regarding use of non-GAAP financial measures

The company reports non-GAAP results for diluted net income per share,
net income, gross margins, operating expenses, operating margins, other
income, and free cash flow in addition to, and not as a substitute for,
or superior to, financial measures calculated in accordance with GAAP.

The company’s financial measures under GAAP include substantial charges
such as stock compensation expense, amortization of acquired intangible
assets, non-cash interest expense associated with the company’s
convertible debt instruments that may be settled in cash, and others
that are listed in the itemized reconciliations between GAAP and
non-GAAP financial measures included in this press release. Management
believes that presentation of operating results that excludes these
items provides useful supplemental information to investors and
facilitates the analysis of the company’s core operating results and
comparison of operating results across reporting periods. Management
also believes that this supplemental non-GAAP information is therefore
useful to investors in analyzing and assessing the company’s past and
future operating performance.

The company encourages investors to carefully consider its results under
GAAP, as well as its supplemental non-GAAP information and the
reconciliation between these presentations, to more fully understand its
business. Reconciliations between GAAP and non-GAAP results are
presented in the tables of this release.

Use of forward-looking statements

This release contains projections, information about our financial
outlook, earnings guidance, and other forward-looking statements that
involve risks and uncertainties. These forward-looking statements are
based on our expectations as of the date of this release and may differ
materially from actual future events or results. Among the important
factors that could cause actual results to differ materially from those
in any forward-looking statements are (i) our ability to further develop
and commercialize our instruments and consumables and to deploy new
products, services, and applications, and expand the markets, for our
technology platforms; (ii) our ability to manufacture robust
instrumentation and consumables; (iii) our ability to successfully
identify and integrate acquired technologies, products, or businesses;
(iv) our expectations and beliefs regarding future conduct and growth of
the business and the markets in which we operate; (v) challenges
inherent in developing, manufacturing, and launching new products and
services; and (vi) the application of generally accepted accounting
principles, which are highly complex and involve many subjective
assumptions, estimates, and judgments, together with other factors
detailed in our filings with the Securities and Exchange Commission,
including our most recent filings on Forms 10-K and 10-Q, or in
information disclosed in public conference calls, the date and time of
which are released beforehand. We undertake no obligation, and do not
intend, to update these forward-looking statements, to review or confirm
analysts’ expectations, or to provide interim reports or updates on the
progress of the current quarter.

About Illumina

Illumina is improving human health by unlocking the power of the genome.
Our focus on innovation has established us as the global leader in DNA
sequencing and array-based technologies, serving customers in the
research, clinical and applied markets. Our products are used for
applications in the life sciences, oncology, reproductive health,
agriculture and other emerging segments. To learn more, visit www.illumina.com and
follow @illumina.

 
Illumina, Inc.
Condensed Consolidated Balance Sheets
(In thousands)
 
      January 3,       December 28,
2016 2014
ASSETS (unaudited)
Current assets:
Cash and cash equivalents $ 768,770 $ 636,154
Short-term investments 617,450 702,217
Accounts receivable, net 385,529 289,458
Inventory 270,777 191,144
Deferred tax assets, current portion 40,786
Prepaid expenses and other current assets   54,297   29,844
Total current assets 2,096,823 1,889,603
Property and equipment, net 342,694 265,264
Goodwill 752,629 724,904
Intangible assets, net 273,621 314,500
Deferred tax assets, long-term portion 134,515 49,848
Other assets   87,465   95,521
Total assets $ 3,687,747 $ 3,339,640
 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable $ 139,226 $ 82,626
Accrued liabilities 396,339 335,276
Long-term debt, current portion   74,929   304,256
Total current liabilities 610,494 722,158
Long-term debt 1,015,649 986,780
Other long-term liabilities 180,505 167,904
Redeemable noncontrolling interests 32,546
Stockholders’ equity   1,848,553   1,462,798
Total liabilities and stockholders’ equity $ 3,687,747 $ 3,339,640
 
 
Illumina, Inc.
Condensed Consolidated Statements of Income
(In thousands, except per share amounts)
(unaudited)
 
      Three Months Ended       Years Ended
January 3,       December 28, January 3,       December 28,
2016 2014 2016 2014
Revenue:
Product revenue $ 497,922 $ 450,329 $ 1,890,633 $ 1,619,511
Service and other revenue   93,626     62,050     329,129     241,847  
Total revenue   591,548     512,379     2,219,762     1,861,358  
Cost of revenue:
Cost of product revenue (a) 130,775 93,069 490,812 431,920
Cost of service and other revenue (a) 39,561 23,757 133,850 92,355
Amortization of acquired intangible assets   10,853     10,616     45,810     39,373  
Total cost of revenue   181,189     127,442     670,472     563,648  
Gross profit   410,359     384,937     1,549,290     1,297,710  
Operating expense:
Research and development (a) 114,347 142,947 401,527 388,055
Selling, general and administrative (a) 147,251 122,173 524,657 466,283
Legal contingencies 4,000 (82,043 ) 19,000 (74,338 )
Headquarter relocation 436 1,281 (2,611 ) 5,638
Acquisition related expense (gain), net   325     (2,304 )   (6,124 )   (2,639 )
Total operating expense   266,359     182,054     936,449     782,999  
Income from operations 144,000 202,883 612,841 514,711
Other expense, net   (8,993 )   (10,822 )   (29,699 )   (65,953 )
Income before income taxes 135,007 192,061 583,142 448,758
Provision for income taxes   32,143     38,781     125,752     95,407  
Consolidated net income 102,864 153,280 457,390 353,351
Add: Net loss attributable to noncontrolling interests   1,613         4,169      
Net income attributable to Illumina stockholders $ 104,477   $ 153,280   $ 461,559   $ 353,351  
Earnings per share attributable to Illumina stockholders:
Basic $ 0.72 $ 1.08 $ 3.19 $ 2.61
Diluted $ 0.70 $ 1.03 $ 3.10 $ 2.37
Shares used in computing earnings per common share:
Basic 145,963 142,342 144,826 135,553
Diluted 148,952 148,657 149,069 148,977
                                 
(a) Includes total stock-based compensation expense for
stock-based awards:
 
Three Months Ended Years Ended
January 3, December 28, January 3, December 28,
2016 2014 2016 2014
Cost of product revenue $ 2,829 $ 2,635 $ 9,841 $ 9,451
Cost of service and other revenue 366 324 1,609 1,204
Research and development 10,849 11,837 42,001 50,880
Selling, general and administrative   21,445     23,666     79,142     91,016  
Stock-based compensation expense before taxes $ 35,489   $ 38,462   $ 132,593   $ 152,551  
 
 
Illumina, Inc.
Condensed Consolidated Statements of Cash Flows
(In thousands)
(unaudited)
 
      Three Months Ended       Years Ended
January 3,       December 28, January 3,       December 28,
2016 2014 2016 2014
Net cash provided by operating activities (a) $ 240,378 $ 140,549 $ 659,596 $ 501,271
Net cash provided by (used in) investing activities 229,398 (332,783 ) (106,146 ) (406,624 )
Net cash (used in) provided by financing activities (a) (253,141 ) 202 (418,762 ) (166,748 )
Effect of exchange rate changes on cash and cash equivalents   606     (1,709 )   (2,072 )   (3,382 )
Net increase (decrease) in cash and cash equivalents 217,241 (193,741 ) 132,616 (75,483 )
Cash and cash equivalents, beginning of period   551,529     829,895     636,154     711,637  
Cash and cash equivalents, end of period $ 768,770   $ 636,154   $ 768,770   $ 636,154  
 
Calculation of free cash flow:
Net cash provided by operating activities (a) $ 240,378 $ 140,549 $ 659,596 $ 501,271
Purchases of property and equipment   (35,486 )   (34,832 )   (142,847 )   (105,996 )
Free cash flow (b) $ 204,892   $ 105,717   $ 516,749   $ 395,275  
 

(a) Net cash provided by operating activities excludes excess tax
benefit related to stock-based compensation of $126.7 million in fiscal
2015, of which $5.0 million was recorded in Q4, and $126.5 million in
fiscal 2014, of which $23.8 million was recorded in Q4. Net cash used in
financing activities reflects the excess tax benefit as a corresponding
in-flow in the respective periods.

(b) Free cash flow, which is a non-GAAP financial measure, is
calculated as net cash provided by operating activities reduced by
purchases of property and equipment. Free cash flow is useful to
management as it is one of the metrics used to evaluate our performance
and to compare us with other companies in our industry. However, our
calculation of free cash flow may not be comparable to similar measures
used by other companies.

 
Illumina, Inc.
Results of Operations – Non-GAAP
(In thousands, except per share amounts)
(unaudited)
 
ITEMIZED RECONCILIATION BETWEEN GAAP AND NON-GAAP EARNINGS PER
SHARE ATTRIBUTABLE TO ILLUMINA STOCKHOLDERS:
                       
Three Months Ended Years Ended
January 3, December 28, January 3, December 28,
2016 2014 2016 2014
GAAP earnings per share attributable to Illumina stockholders –
diluted
$ 0.70 $ 1.03 $ 3.10 $ 2.37
Amortization of acquired intangible assets 0.09 0.08 0.35 0.32
Non-cash interest expense (a) 0.06 0.07 0.26 0.26
Legal contingencies (b) 0.03 (0.40 ) 0.13 (0.24 )
Contingent compensation expense (c) 0.03
Headquarter relocation 0.01 (0.02 ) 0.04
Loss on extinguishment of debt 0.03 0.21
Acquisition related expense (gain), net (d) (0.02 ) (0.04 ) (0.02 )
Cost-method investment gain, net (e) (0.10 ) (0.03 )
Tax benefit related to cost-sharing arrangement (f) (0.17 )
Incremental non-GAAP tax (expense) benefit (g)   (0.07 )   0.10     (0.22 )   (0.20 )
Non-GAAP earnings per share attributable to Illumina stockholders –
diluted (h)
$ 0.81   $ 0.87   $ 3.32   $ 2.74  
Shares used in calculating non-GAAP diluted earnings per share
attributable to Illumina stockholders
  148,952     148,657     149,069     148,815  
 
ITEMIZED RECONCILIATION BETWEEN GAAP AND NON-GAAP NET INCOME
ATTRIBUTABLE TO ILLUMINA STOCKHOLDERS:
 
GAAP net income attributable to Illumina stockholders $ 104,477 $ 153,280 $ 461,559 $ 353,351
Amortization of acquired intangible assets 12,376 12,203 51,829 48,165
Non-cash interest expense (a) 8,705 10,099 38,589 38,154
Legal contingencies (b) 4,000 (59,483 ) 19,000 (35,931 )
Contingent compensation expense (c) 685 433 934 4,265
Headquarter relocation 436 1,281 (2,611 ) 5,638
Loss on extinguishment of debt 325 4,062 31,360
Acquisition related expense (gain), net (d) 325 (2,304 ) (6,124 ) (2,639 )
Cost-method investment gain, net (e) (119 ) (15,601 ) (4,427 )
Impairments (i) (485 ) (485 )
Tax benefit related to cost-sharing arrangement (f) (56 ) (24,813 )
Incremental non-GAAP tax (expense) benefit (g)   (10,584 )   13,925     (31,621 )   (30,234 )
Non-GAAP net income attributable to Illumina stockholders (h) $ 120,570   $ 128,949   $ 495,203   $ 407,217  
 
ITEMIZED RECONCILIATION BETWEEN GAAP AND NON-GAAP DILUTED NUMBER
OF SHARES ATTRIBUTABLE TO ILLUMINA STOCKHOLDERS:
 
Weighted average shares used in calculation of GAAP diluted earnings
per share
148,952 148,657 149,069 148,977
Weighted average dilutive potential common shares issuable of
redeemable convertible senior notes
              (162 )
Weighted average shares used in calculation of non-GAAP diluted
earnings per share attributable to Illumina stockholders
  148,952     148,657     149,069     148,815  
 

(a) Non-cash interest expense is calculated in accordance with
the authoritative accounting guidance for convertible debt instruments
that may be settled in cash.

(b) Legal contingencies in fiscal 2015 represent charges related
to patent litigation. Legal contingencies in fiscal 2014 primarily
represent a gain related to the settlement of our patent litigation with
Syntrix Biosystems, Inc., partially offset by the expenses recorded upon
our litigation settlement and pooling of patents with Sequenom, Inc.

(c) Contingent compensation expense relates to contingent
payments for post-combination services associated with an acquisition.

(d) Acquisition related expense (gain), net consists of changes
in fair value of contingent consideration and transaction related costs.

(e) Cost-method investment gain, net consists primarily of gains
on disposition of investments partially offset by impairment charges on
other investments.

(f) Tax benefit related to cost-sharing arrangement refers to the
exclusion of stock compensation from prior period cost-sharing charges
as a result of a recent tax court ruling.

(g) Incremental non-GAAP tax (expense) benefit reflects the tax
impact related to the non-GAAP adjustments listed above.

(h) Non-GAAP net income attributable to Illumina stockholders and
diluted earnings per share attributable to Illumina stockholders exclude
the effect of the pro forma adjustments as detailed above. Non-GAAP net
income attributable to Illumina stockholders and diluted earnings per
share attributable to Illumina stockholders are key drivers of the
Company’s core operating performance and major factors in management’s
bonus compensation each year. Management has excluded the effects of
these items in these measures to assist investors in analyzing and
assessing our past and future core operating performance.

(i) Impairments in fiscal 2014 consisted of a gain on an asset
sale associated with a non-core product line discontinued in 2013,
partially offset by an intangible asset impairment.

 
Illumina, Inc.
Results of Operations – Non-GAAP (continued)
(Dollars in thousands)
(unaudited)
 
ITEMIZED RECONCILIATION BETWEEN GAAP AND NON-GAAP RESULTS OF
OPERATIONS AS A PERCENT OF REVENUE:
 
      Three Months Ended       Years Ended
January 3,       December 28, January 3,       December 28,
2016 2014 2016 2014
GAAP gross profit $ 410,359       69.4 % $ 384,937       75.1 % $ 1,549,290       69.8 % $ 1,297,710       69.7 %
Stock-based compensation expense 3,195 0.5 % 2,959 0.6 % 11,450 0.5 % 10,655 0.6 %
Amortization of acquired intangible assets 10,853 1.8 % 10,616 2.1 % 45,810 2.1 % 39,373 2.1 %
Legal contingencies (a) (26,240 ) (5.1 )% (10,393 ) (0.6 )%
Impairments (b)         (2,000 ) (0.4 )%         (2,000 ) (0.1 )%
Non-GAAP gross profit (c) $ 424,407   71.7 % $ 370,272   72.3 % $ 1,606,550   72.4 % $ 1,335,345   71.7 %
 
GAAP research and development expense $ 114,347 19.3 % $ 142,947 27.9 % $ 401,527 18.1 % $ 388,055 20.8 %
Stock-based compensation expense (10,849 ) (1.8 )% (11,837 ) (2.3 )% (42,001 ) (1.9 )% (50,880 ) (2.7 )%
Contingent compensation expense (d) (83 ) (433 ) (0.1 )% (127 ) (1,509 ) (0.1 )%
Legal contingencies (a) (48,800 ) (9.5 )% (48,800 ) (2.6 )%
Impairments (b)         (1,515 ) (0.3 )%         (1,515 ) (0.1 )%
Non-GAAP research and development expense $ 103,415   17.5 % $ 80,362   15.7 % $ 359,399   16.2 % $ 285,351   15.3 %
 
GAAP selling, general and administrative expense $ 147,251 24.9 % $ 122,173 23.8 % $ 524,657 23.6 % $ 466,283 25.1 %
Stock-based compensation expense (21,445 ) (3.6 )% (23,666 ) (4.6 )% (79,142 ) (3.5 )% (91,016 ) (4.9 )%
Amortization of acquired intangible assets (1,523 ) (0.3 )% (1,587 ) (0.3 )% (6,019 ) (0.3 )% (8,792 ) (0.6 )%
Contingent compensation expense (d)   (602 ) (0.1 )%         (807 )     (2,756 ) (0.1 )%
Non-GAAP selling, general and administrative expense $ 123,681   20.9 % $ 96,920   18.9 % $ 438,689   19.8 % $ 363,719   19.5 %
 
GAAP operating profit $ 144,000 24.3 % $ 202,883 39.6 % $ 612,841 27.6 % $ 514,711 27.7 %
Stock-based compensation expense 35,489 6.0 % 38,462 7.5 % 132,593 5.9 % 152,551 8.2 %
Amortization of acquired intangible assets 12,376 2.1 % 12,203 2.4 % 51,829 2.4 % 48,165 2.6 %
Legal contingencies (a) 4,000 0.7 % (59,483 ) (11.6 )% 19,000 0.9 % (35,931 ) (1.9 )%
Contingent compensation expense (d) 685 0.1 % 433 0.1 % 934 4,265 0.2 %
Headquarter relocation 436 0.1 % 1,281 0.2 % (2,611 ) (0.1 )% 5,638 0.2 %
Acquisition related expense (gain), net (e) 325 0.1 % (2,304 ) (0.4 )% (6,124 ) (0.3 )% (2,639 ) (0.1 )%
Impairments (b)         (485 ) (0.1 )%         (485 )  
Non-GAAP operating profit (c) $ 197,311   33.4 % $ 192,990   37.7 % $ 808,462   36.4 % $ 686,275   36.9 %
 
GAAP other expense, net $ (8,993 ) (1.5 )% $ (10,822 ) (2.1 )% $ (29,699 ) (1.3 )% $ (65,953 ) (3.5 )%
Non-cash interest expense (f) 8,705 1.5 % 10,099 2.0 % 38,589 1.7 % 38,154 2.0 %
Loss on extinguishment of debt 325 4,062 0.2 % 31,360 1.7 %
Cost-method investment gain, net (g)   (119 )           (15,601 ) (0.7 )%   (4,427 ) (0.2 )%
Non-GAAP other expense, net (c) $ (82 )   $ (723 ) (0.1 )% $ (2,649 ) (0.1 )% $ (866 )  
 

Contacts

Illumina, Inc.
Investors:
Rebecca Chambers
858.255.5243
rchambers@illumina.com
or
Media:
Eric
Endicott
858.882.6822
pr@illumina.com

Read full story here